Method: a-Tocopherol and g-tocopherol are metabolized into 2,5,7,8-tetramethyl-2-(2 0 -carboxyethyl)-6-hydroxychroman (a-CEHC) and 2,7,8-trimethyl-2-(2 0 -carboxyethyl)-6-hydroxychroman (g-CEHC), respectively. We analyzed a-and g-CEHC concentrations in human serum and urine by high-performance liquid chromatography during administration of a-tocopherol. Fourteen healthy adult male volunteers received 1200 IU per day of RRR-a-tocopherol for 28 days. Blood and urine samples were obtained on days 0, 14, 28, and 56. Results: During a-tocopherol administration, the plasma g-tocopherol concentration decreased significantly, but there was marked elevation of the a-tocopherol concentration. Increased concentration of a-CEHC and g-CEHC in both serum and urine indicated the acceleration of vitamin E metabolism. Conclusion: High-dose administration of a-tocopherol caused an increase of g-tocopherol metabolism, which might have caused a decrease of the plasma g-tocopherol concentration.
Introduction
It is known that administration of a-tocopherol results in a decrease of the plasma g-tocopherol concentration (Handelman et al, 1985; Kayden & Traber, 1993; Kitagawa & Mino, 1989) . This reduction of g-tocopherol during a-tocopherol administration may be due to competition between a-tocopherol and g-tocopherol for binding sites in the intestine, or due to involvement of a-tocopherol transfer protein (aTTP). It is also possible that the rate of g-tocopherol metabolism is highly dependent on the nutritional status of a-tocopherol (Kitagawa & Mino, 1989) . At present, the reason why plasma g-tocopherol is reduced by oral administration of a-tocopherol has not been clearly explained.
2,8-Dimethyl-2-(2 0 -carboxyethyl)-6-chromanol is a metabolite of d-tocopherol with an intact chroman ring that was discovered in rat urine in 1984 (Chiku et al, 1984) . Recently, the vitamin E metabolites in human specimens have been analyzed by high-performance liquid chromatography (HPLC; Lodge et al, 2000; Stahl et al, 1999) or gas chromatography mass spectrometry (GC=MS) (Schultz et al, 1995; Swanson et al, 1999) . Schultz reported that urinary 2,5,7,8-tetramethyl-2(2 0 -carboxyethyl)-6-hydroxychroman (a-CEHC) excretion might be considered to be a marker of optimum vitamin E intake (Schultz et al, 1995) . Stahl investigated the plasma levels of a-CEHC and 2,7,8-trimethyl-2(2 0 -carboxyethyl)-6-hydroxychroman (g-CEHC) in healthy adults taking a-tocopherol, and reported that there was only a slight elevation of g-CEHC (Stahl et al, 1999) . Kiyose demonstrated the excretion of g-CEHC after a-and g-tocopherol supplementation in vitamin E deficient rats, and suggested a-tocopherol might affect the metabolism of gtocopherol to g-CEHC (Kiyose et al, 2001) . It is also known that tocotrienols, other members of the vitamin E family, are metabolized to CEHCs as well as tocopherols and then excreted in the urine (Lodge et al, 2001 ).
In the present study, we investigated the concentrations of tocopherols and CEHCs in healthy male volunteers during administration of a-tocopherol. We discuss the metabolism of vitamin E during supplementation, mainly with respect to the decrease of plasma g-tocopherol.
Subjects and methods
Chemicals a, g-Tocopherol and a, g-CEHC were obtained from Eisai Co. b-Glucuronidase from E. coli, butylated hydroxytoluene (BHT), hydrochloride, hexane, diethylether and dichloromethane were obtained from Nacalai Tesque Co. (Kyoto, Japan). b-Glucuronidase containing sulfatase activity (type H-1) from Helix pomatia was obtained from Sigma.
Subjects
Fourteen healthy adult male volunteers were enrolled in this study. Their mean age was 29.3 (s.d. 3.4) y and mean weight was 62.2 (s.d. 5.7) kg. None of them were taking regular vitamin supplements. All volunteers received 1200 IU (800 mg) of RRR-a-tocopherol daily by oral administration after meals (300 IU in the morning, 450 IU each in the afternoon and evening) for 28 days. After an overnight fast, blood was obtained from each volunteer on day 0 (before administration), day 14, day 28 and day 56 (after cessation of vitamin E supplementation). The first morning urine was also obtained from seven volunteers on the days of blood testing. The study was approved by the ethics committee of Osaka Medical College, and written informed consent was obtained from each subject.
Analysis of vitamin E
Plasma vitamin E levels were measured by HPLC with electrochemical detection, as described previously (Tamai et al, 1988) . Two hundred microliters of plasma was placed into a tube together with 800 ml of phosphate buffer, 1 ml of 6% pyrogallol solution in ethanol and 1 ml of tocol solution in ethanol (2 mg=ml), as an internal standard, which was then preincubated for 2 min at 70 C. After the incubation, the solution mixture was added to 0.2 ml of 60% KOH and saponified at 70 C for 30 min. Following the saponification, the sample solution was mixed with 5 ml of n-hexane, and vigorously shaken for 5 min. After centrifugation at 3000 rpm for 5 min, 4 ml of hexane layer was taken up and evaporated. The residue was dissolved in 100 ml of ethanol, in which 5 ml was injected into HPLC system. The HPLC equipment was an IRIKAS871 (Irika Co. Ltd., Kyoto, Japan) with an IRIKA QC pack, 4Â250 mm column. Eluents were methanol=water=NaClO 4 in a ratio of 1000=2=7 (v=v=w). Flow rate was 1.0 ml=min. The detector was an IRIKAS875 amperometric detector with 700mV of applied potential.
Analysis of CEHC
Plasma and urinary concentrations of CEHC were analyzed by HPLC, as reported previously (Lodge et al, 2000; Stahl et al, 1999) with slight modifications. Twenty-five thousand units of b-glucronidase were dissolved in 2.5 ml of 0.1 mol=l acetate buffer (pH 4.5) on ice and used to hydrolyze the conjugate immediately after preparation.
One thousand units (0.1 ml) of b-glucuronidase solution was added to 1 ml of urine, and was incubated for 120 min at 37 C to hydrolyze the conjugate. After cooling on ice, 50 ml of 6 mol=l HCl and 3 ml of diethylether were added, and the mixture was centrifuged (2000 rpm, 2 min). Two milliliters of the supernatant were collected into another tube and evaporated to dryness, after which the residue was dissolved in 4 ml of ethanol with 0.015% BHT. Then 5ml aliquots of the resulting solution were injected into the HPLC system. To confirm whether an incubation time of 2 h and 1000 IU of bglucuronidase were suitable to hydrolyze the conjugate, we analyzed urinary CEHCs under the following conditions. CEHCs were measured after different incubation times (0, 1, 2 and 4 hours) and using different amounts of bglucuronidase (0, 500, 1000 and 2000 IU). Urinary CEHC was expressed as the urinary CEHC to creatinine ratio. Creatinine was measured by CreatinineTest Wako kit (Wako Chemical Co., Osaka, Japan).
Five hundred microliters of serum were prepared, and 25 ml of ascorbic acid (10 mg=ml water) and 2000 U of bglucuronidase were added. After incubation for 2 h at 37 C and cooling were done, 5 ml of extraction solvent (50% hexane, 50% dichloromethane and 0.1% BHT) was pipetted into the mixture. Following vortexing and centrifugation at 5000 rpm for 5 min, 4 ml of the supernatant were evaporated to dryness. Then the residue was dissolved in 200 ml of ethanol and a 20 ml aliquot was injected into the HPLC system.
The HPLC system consisted of an IRICAS871 pump (Irica Co. Ltd, Kyoto, Japan), a NanoSpace Amperometer (Shiseido Co. Ltd, Tokyo, Japan) with 550 mV of applied potential, and an ODS III C 18 column (5 mm, 2.1Â250 mm, GL Science). The column temperature was kept at 37 C. Elution was done with a mixture of 40% acetnitrile and 60% H 2 O containing 50 mmol=l NaClO 4 (pH 3.6), and the flow rate was 0.2 ml=min. To determine the optimum voltage for electrochemical detection, the peak areas of a-CEHC and g-CEHC were obtained at different applied potentials. The injection volume for the voltamogram was 41.3 pmol for g-CEHC and 17.2 pmol for a-CEHC.
Recovery and coefficient of variation (CV)
Recovery of CEHCs was ascertained by comparing the peak areas when the standards were added directly to urine and extracted, or were added to urine extracts immediately before analysis. We analyzed CEHCs using a calibration curve, and the CV was measured to assess the reproducibility of the method. 
Results
The voltamogram showed a plateau when the potential applied was over 500 mV for g-CEHC and over 450 mV for a-CEHC (Figure 1 ), so 550 mV was chosen as the optimum oxidation potential for ECD. Using this voltage, the peaks of a-and g-CEHC were clearly separated on chromatograms of both the standard solution and urine samples, as shown in Figure 2 . The retention time was 14 min for g-CEHC and 19 min for a-CEHC. The recovery rate of a-and g-CEHC from urine was 93.8 and 99.7%, respectively, while the recovery rate from serum was 100 and 94.7%. CV values obtained from five samples were 4.3, 3.3, 5.0 and 6.0% for each of the above-mentioned CEHCs, respectively. In a preliminary study, we used sulfatase with b-glucuronidase (type H-1) to hydrolyze the conjugate. Since we could obtain the same amount of CEHC with or without sulfatase (data not shown), b-glucuronidase alone was used for hydrolysis in the present study. Figure 3 shows the changes in the area of urinary CEHCs with different incubation times. The area showed a plateau after 1 h for both a-and g-CEHC. Furthermore, when the amount of enzyme was over 500 IU, the area remained the same (Figure 4) . From these findings, suitable conditions 
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T Morinobu et al for hydrolysis of the conjugate were set at 1000 IU of bglucuronidase for 2 h. The baseline plasma concentration of a-tocopherol was higher than that of g-tocopherol, while the serum concentration of a-CEHC was lower than that of g-CEHC (Table 1) . The plasma a-tocopherol concentration was markedly increased during administration, while a significant decrease of g-tocopherol was seen (Table 1) . Although we found an increase of serum a-CEHC during a-tocopherol administration, as occurred with plasma a-tocopherol, the serum concentration of g-CEHC was also significantly elevated, unlike the change of plasma g-tocopherol. Urinary excretion of both a-and g-CEHC was also increased during a-tocopherol administration ( Table 2) .
Discussion
In the present study, we analyzed a-and g-CEHC by the previously reported method (Lodge et al, 2000; Stahl et al, 1999) with slight modifications. Although we used a nongradient HPLC system, clear separation of the CEHC peaks was obtained. The enzyme b-glucuronidase was used in the present study, which was different from that which Lodge reported previously. Therefore, we investigated suitable conditions for hydrolysis of the conjugate using this enzyme, and chose incubation with 1000 IU of b-glucuronidase for 2 h. We employed a calibration curve rather than an internal standard, but we were still able to obtain good recovery and a good CV, so this method is thought to be suitable for the measurement of CEHCs.
Little is known about the factors regulating vitamin E metabolism. It has been reported that the intake of sesame seeds and sesame lignan can cause a marked increase of the a-tocopherol concentration in the blood and tissues of rats (Yamashita et al, 1995) , and that sesamin inhibits the metabolism of tocopherol to CEHC by HepG2=C3A cells (Parker et al, 2000) . Parker also studied the metabolism of tocopherol to CEHC by cultured cells and the inhibition of its metabolism by ketoconozole, and suggested that cytochrome P4503A might be involved in vitamin E metabolism (Parker et al, 2000) .
In Japan, the dietary intake of g-tocopherol (about 13 mg=day) is known to be 1.4 times higher than that of atocopherol (personal communication). The serum concentration of g-CEHC was 10 times higher than that of a-CEHC and the urine level was five times higher before a-tocopherol administration, even though the daily dietary intake of gtocopherol was slightly higher than that of a-tocopherol. aTTP is known to carry a-tocopherol selectively into the blood and tissues, while g-tocopherol is excreted in the bile and=or urine. In the present study, the g-CEHC concentration before supplementation was much higher than a-tocopherol concentration. g-Tocopherol, not bound to aTTP, was metabolized to g-CEHC, and excreted in the bile and urine. This may be one of the reasons why there was a discrepancy between the plasma concentrations of a-and g-tocopherol. Accelerated metabolism of g-tocopherol during a-tocopherol administration might be due to the induction of an enzyme which catabolizes a-tocopherol, as described in the former study mentioned above (Parker et al, 2000) , and this may explain the reduction of plasma g-tocopherol during a-tocopherol administration. In the present study, we used the morning urine for measurement of CEHCs. The excretion of CEHCs is known to be affected by administration of atocopherol (Lodge et al, 2000) . Although a 24 h urine specimen is more suitable to analyze urinary CEHC levels, morning urine can also be employed to compare the excretion of CEHCs before and after a-tocopherol supplementation, Mean AE s.d. *P < 0.01 compared for day 0.
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provided that a-tocopherol is administered to the subjects at the same time and urine samples are obtained from them at the same time of day. Ataxia with isolated vitamin E deficiency (AVED) is a rare inherited disease that is characterized by a defect of aTTP (Ouahchi et al, 1995) . Although the plasma vitamin E concentration is extremely low in AVED patients, Schuelke reported that the urinary a-CEHC level of a patient with AVED was higher than that in normal controls, and suggested that a-tocopherol which exceeded the capacity of a-TTP was degraded and excreted into the urine as a-CEHC, rather than being transferred into VLDL (Schuelke et al, 2000) . Because aTTP is known to have a low affinity for gtocopherol (Hosomi et al, 1997) , aTTP might also be involved in the transport of g-tocopherol from the liver into the bloodstream. During a-tocopherol administration, aTTP may become saturated with a-tocopherol in the liver, and g-tocopherol unbound to a-TTP might be metabolized to g-CEHC and excreted into the urine.
In the present report, we presented a simple method for measuring CEHCs in human serum and urine. Using this method, we found an explanation for the reduced g-tocopherol level during high-dose administration of a-tocopherol (1200 U=day).
